Novel Use of Surveillance Data to Detect HIV-Infected Persons with Sustained High Viral Load and Durable Virologic Suppression in New York City

Background Monitoring of the uptake and efficacy of ART in a population often relies on cross-sectional data, providing limited information that could be used to design specific targeted intervention programs. Using repeated measures of viral load (VL) surveillance data, we aimed to estimate and characterize the proportion of persons living with HIV/AIDS (PLWHA) in New York City (NYC) with sustained high VL (SHVL) and durably suppressed VL (DSVL). Methods/Principal Findings Retrospective cohort study of all persons reported to the NYC HIV Surveillance Registry who were alive and ≥12 years old by the end of 2005 and who had ≥2 VL tests in 2006 and 2007. SHVL and DSVL were defined as PLWHA with 2 consecutive VLs ≥100,000 copies/mL and PLWHA with all VLs ≤400 copies/mL, respectively. Logistic regression models using generalized estimating equations were used to model the association between SHVL and covariates. There were 56,836 PLWHA, of whom 7% had SHVL and 38% had DSVL. Compared to those without SHVL, persons with SHVL were more likely to be younger, black and have injection drug use (IDU) risk. PLWHA with SHVL were more likely to die by 2007 and be younger by nearly ten years, on average. Conclusions/Significance Nearly 60% of PLWHA in 2005 had multiple VLs, of whom almost 40% had DSVL, suggesting successful ART uptake. A small proportion had SHVL, representing groups known to have suboptimal engagement in care. This group should be targeted for additional outreach to reduce morbidity and secondary transmission. Measures based on longitudinal analyses of surveillance data in conjunction with cross-sectional measures such as community viral load represent more precise and powerful tools for monitoring ART effectiveness and potential impact on disease transmission than cross-sectional measures alone.

[1]  S. Marhefka,et al.  “I feel like I'm carrying a weapon.” Information and motivations related to sexual risk among girls with perinatally acquired HIV , 2011, AIDS care.

[2]  T. Hallett,et al.  Late Entry to HIV Care Limits the Impact of Anti-Retroviral Therapy in the Netherlands , 2008, PloS one.

[3]  M. Das,et al.  Linkage and retention in HIV care among men who have sex with men in the United States. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  T. Frieden,et al.  Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. , 2008, Archives of internal medicine.

[5]  T. Rhodes,et al.  Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed , 2010, The Lancet.

[6]  S. Buskin,et al.  Continued risky behavior in HIV-infected youth. , 2000, American journal of public health.

[7]  B. Branson,et al.  Vital signs: HIV testing and diagnosis among adults--United States, 2001-2009. , 2010, MMWR. Morbidity and mortality weekly report.

[8]  M. Sharland,et al.  Young people in the United Kingdom and Ireland with perinatally acquired HIV: the pediatric legacy for adult services. , 2009, AIDS patient care and STDs.

[9]  L. Torian,et al.  Continuity of HIV-related medical care, New York City, 2005-2009: Do patients who initiate care stay in care? , 2011, AIDS patient care and STDs.

[10]  R. Bakeman,et al.  Explaining disparities in HIV infection among black and white men who have sex with men: a meta-analysis of HIV risk behaviors , 2007, AIDS.

[11]  M. Hughes,et al.  Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy , 2011, AIDS.

[12]  L. Espinoza,et al.  Epidemiology of HIV Infection in Large Urban Areas in the United States , 2010, PloS one.

[13]  C. Rouzioux,et al.  Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level , 2003, AIDS.

[14]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[15]  Martina Morris,et al.  Concurrent partnerships and HIV prevalence disparities by race: linking science and public health practice. , 2009, American journal of public health.

[16]  Richard D Moore,et al.  Late presentation for human immunodeficiency virus care in the United States and Canada. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  D. Wolfe,et al.  Human Rights and HIV Prevention, Treatment, and Care for People Who Inject Drugs: Key Principles and Research Needs , 2010, Journal of acquired immune deficiency syndromes.

[18]  H. Hagan,et al.  Reconsidering the Internet as an HIV/STD Risk for Men Who Have Sex with Men , 2010, AIDS and Behavior.

[19]  Mark Dybul,et al.  Guidelines for Using Antiretroviral Agents among HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV* , 2002, Annals of Internal Medicine.

[20]  H. Sørensen,et al.  Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study. , 2006, Clinical Infectious Diseases.

[21]  Connie Celum,et al.  Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis , 2010, The Lancet.

[22]  Lisa M. Lee,et al.  Classification of transmission risk in the national HIV/AIDS surveillance system. , 2003, Public health reports.

[23]  J. Dunbar,et al.  Short report: migration among persons living with HIV. , 2003, Social science & medicine.

[24]  R. Greenblatt,et al.  Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART. , 2009, Journal of women's health.

[25]  J. Stephenson,et al.  Health agencies update: HIV prevention trials network , 2000, JAMA.

[26]  S. Chandwani,et al.  Sexual Transmission Risk Behavior of Adolescents With HIV Acquired Perinatally or Through Risky Behaviors , 2010, Journal of acquired immune deficiency syndromes.

[27]  Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Centers for Disease Control and Prevention. , 1999, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[28]  Evan Wood,et al.  Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study , 2009, BMJ : British Medical Journal.

[29]  D R Hoover,et al.  Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. , 2001, The New England journal of medicine.

[30]  Kai-lih Liu,et al.  Continuing HIV Risk in New York City Injection Drug Users: The Association of Syringe Source and Syringe Sharing , 2011, Substance use & misuse.

[31]  T. Hallett,et al.  HIV and risk environment for injecting drug users: the past, present, and future , 2010, The Lancet.

[32]  L. Koenig,et al.  Adolescents with perinatally acquired HIV: emerging behavioral and health needs for long-term survivors , 2011, Current opinion in obstetrics & gynecology.

[33]  Jeffrey N. Martin,et al.  Decline in HIV infectivity following the introduction of highly active antiretroviral therapy , 2003, AIDS.

[34]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[35]  Matthias Egger,et al.  Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.

[36]  Nedjeljko Frančula The National Academies Press , 2013 .

[37]  E. Vittinghoff,et al.  Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco , 2010, PloS one.

[38]  R. Hogg,et al.  Expanded Highly Active Antiretroviral Therapy Coverage Among HIV-Positive Drug Users to Improve Individual and Public Health Outcomes , 2010, Journal of acquired immune deficiency syndromes.